VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Financial Statements and ExhibitsItem 9.01.
Vanda Pharmaceuticals Inc. ExhibitEX-99.1 2 d362084dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Vandas Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis Worst Itch Visual Analog Scale (Worst Itch VAS): Tradipitant vs. Placebo p=0.019 Scoring Atopic Dermatitis (SCORAD): Tradipitant vs. Placebo p=0.008 Management to host conference call on Thursday,…To view the full exhibit click here
About VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.